GOSS

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

Retrieved on: 
火曜日, 5月 14, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, GOSS, Biomarker, Pulmonary hypertension, PAH, Treatment, Orthostatic hypertension, Conference, CSF1R, PDGFR, Fibrosis, Poster, Hemodynamics, Pharmaceutical industry

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22 in San Diego, California.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22 in San Diego, California.
  • Details for the oral presentation related to seralutinib, an inhaled, PDGFR, CSF1R and c-KIT inhibitor, designed for the treatment of pulmonary hypertension, are as follows:
    Gossamer also will present additional data on seralutinib via poster.
  • Details for those posters are as follows:
    Poster Title: TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation, and Fibrosis Improve with Treatment
    Poster Session: D109 Now We Got Bad Blood: RSF/PC Joint Session on Pulmonary Vascular Disease
    Poster Title: Cardiac Effort Is Less Variable Than Six-minute Walk Distance, Correlates with Hemodynamics and Is Consistent with REVEAL 2.0 Risk Score in a Sub-study of the TORREY Phase 2 PAH Trial

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
金曜日, 5月 10, 2024
Biotechnology, Pharmaceutical, Health, Cardiology, GOSS, Employment, PAH, Orthostatic hypertension, Gossamer, Compensated emancipation, Pulmonary hypertension

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective May 8, 2024, to three new non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 323,000 shares of the Company’s common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”).

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective May 8, 2024, to three new non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 323,000 shares of the Company’s common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”).
  • The awards were granted as an inducement material to the employees entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options have an exercise price of $0.755 per share, which is equal to the closing price of Gossamer’s common stock as reported by The Nasdaq Global Select Market on May 8, 2024.
  • The options are subject to the terms and conditions of the 2023 Inducement Plan and the terms and conditions of a stock option agreement covering the grants.

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
火曜日, 5月 7, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Research and development, ATS, Pulmonary hypertension, GOSS, Randomness, Security (finance), The Lancet, PAH, Conference, Orthostatic hypertension, Administration, Public expenditure, Entrepreneurship, Patient, Gossamer, Manuscript, Standard of care, American Thoracic Society, G&A, Pharmaceutical industry

Topline results from the PROSERA Study are expected in the fourth quarter of 2025.

Key Points: 
  • Topline results from the PROSERA Study are expected in the fourth quarter of 2025.
  • On May 6, Gossamer Bio and Chiesi Group announced a development and co-commercialization collaboration for seralutinib.
  • Gossamer and Chiesi will split global development costs for seralutinib, except for the PROSERA Study, for which Gossamer will remain solely responsible.
  • Financial Results for Quarter Ended March 31, 2024
    Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of March 31, 2024, were $244.4 million.

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

Retrieved on: 
月曜日, 5月 6, 2024
Health, Clinical Trials, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Patient, EDT, Pulmonary hypertension, GOSS, PAH, Partnership, ILD, Entrepreneurship, Disease, Prevalence, Orthostatic hypertension, Pharmaceutical industry

Gossamer Bio, Inc. (“Gossamer”) (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, and Chiesi Farmaceutici S.p.A (“Chiesi Group”), an international, research-focused biopharmaceutical group, today announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib.

Key Points: 
  • Gossamer Bio, Inc. (“Gossamer”) (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, and Chiesi Farmaceutici S.p.A (“Chiesi Group”), an international, research-focused biopharmaceutical group, today announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib.
  • While many approved PAH treatments are available, most are primarily vasodilators and do not impact the progressive course of the disease.
  • Gossamer and Chiesi plan to initiate a global Phase 3 registrational study in PH-ILD in mid-2025 and to evaluate seralutinib in additional indications of high unmet need.
  • Chiesi will have the exclusive right to commercialize seralutinib outside of the US and will pay Gossamer an escalating mid-to-high teens royalty on net sales.

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

Retrieved on: 
金曜日, 5月 3, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Pulmonary hypertension, Safety, GOSS, Randomness, The Lancet, PAH, Heart, Disease, Patient, The, PVR, Manuscript, Quality of life, Orthostatic hypertension, Pharmaceutical industry

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the publication of its TORREY Phase 2 study manuscript in the Lancet Respiratory Medicine journal.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the publication of its TORREY Phase 2 study manuscript in the Lancet Respiratory Medicine journal.
  • The paper, titled "Seralutinib in Adults with Pulmonary Arterial Hypertension (TORREY): A Randomized, Double-blind, Placebo-controlled Phase 2 Trial," details the study's significant findings in advancing the treatment of PAH.
  • 86 patients were randomized to receive either seralutinib or placebo by dry powder inhaler twice daily for 24 weeks.
  • Details about PROSERA can be found here: https://clinicaltrials.gov/ct2/show/NCT05934526
    "The publication of the TORREY results in Lancet Respiratory Medicine represents a significant milestone in our ongoing commitment to addressing unmet medical needs for patients with pulmonary hypertension,” said Faheem Hasnain, CEO, Co-founder, and Chairman of Gossamer Bio.

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors

Retrieved on: 
火曜日, 3月 12, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Pulmonary hypertension, Health care, Artificial intelligence, American Thoracic Society, Whitehead Institute, Lung transplantation, Idiopathic pulmonary fibrosis, Medical director, Biomedical Research, Pulmonology, Capital Group Companies, Gossamer, Partnership, American College, Wellesley College, American studies, Commerce, Creative, Medical education, Biomedicine, Latin American studies, International Society, Putnam Investments, MNTN, University, Senior, House, Publication, Portfolio manager, FDA, Internal medicine, Entrepreneurship, Lord Abbett, MIT, Capital, Bloomberg, GOSS, Orthostatic hypertension, IPF, Initial public offering, Partner, Idiopathic disease, PAH, Pharmaceutical industry

Skye Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., and a former Partner and Senior BioPharma Analyst at Capital Group.

Key Points: 
  • Skye Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., and a former Partner and Senior BioPharma Analyst at Capital Group.
  • Ms. Drynan joins the Board with an extensive background in finance, investment, and entrepreneurship, specializing in the biotechnology industry.
  • “The addition of Dr. Nathan to our Board signifies a pivotal moment in Gossamer’s evolution,” said Faheem Hasnain, Co-Founder, Chairman and CEO of Gossamer Bio.
  • Ms. Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., which she founded in 2016.

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
火曜日, 3月 5, 2024
Biotechnology, Pharmaceutical, Health, Cardiology, GOSS, Research, New Drug Application, Research and development, Marketing, Security (finance), Functional, Pulmonary hypertension, Entrepreneurship, PAH, PMDA, Administration, Gossamer, Patient, Public expenditure, Clinical trial, Medication, Orthostatic hypertension, G&A, Pharmaceutical industry

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided a business update.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided a business update.
  • “This advancement marks a significant milestone in Gossamer’s journey, and it was made possible due to the tireless efforts of the Gossamer team.
  • Topline results from the PROSERA Study are expected in the fourth quarter of 2025.
  • Financial Results for Quarter and Full Year Ended December 31, 2023
    Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of December 31, 2023, were $296.4 million.

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
月曜日, 1月 8, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, GOSS, Gossamer, Compensated emancipation, Orthostatic hypertension, Employment, PAH

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective January 5, 2024, to two new non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 212,500 shares of the Company’s common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”).

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective January 5, 2024, to two new non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 212,500 shares of the Company’s common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”).
  • The awards were granted as an inducement material to the employees entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options have an exercise price of $0.85 per share, which is equal to the closing price of Gossamer’s common stock as reported by The Nasdaq Global Select Market on January 5, 2024.
  • The options are subject to the terms and conditions of the 2023 Inducement Plan and the terms and conditions of a stock option agreement covering the grants.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Gossamer Bio, Inc. (NASDAQ: GOSS) and Encourages Investors to Contact the Firm

Retrieved on: 
土曜日, 11月 11, 2023
Acquisition, GOSS, Gossamer

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Gossamer Bio, Inc. (NASDAQ: GOSS) on behalf of the company’s investors.

Key Points: 
  • PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Gossamer Bio, Inc. (NASDAQ: GOSS) on behalf of the company’s investors.
  • Gossamer stockholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.
  • Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis.
  • For additional information about Kaskela Law LLC please visit www.kaskelalaw.com .

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Retrieved on: 
水曜日, 12月 13, 2023
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Webcast, PAH, Patient, GOSS, Pulmonary hypertension, Orthostatic hypertension, CSF1R

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it will host a public conference call and webcast for investors and analysts on Monday, December 18, 2023 at 8:30 am ET to discuss the latest seralutinib clinical data from the ongoing TORREY Phase 2 Open-Label Extension Study in PAH patients.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it will host a public conference call and webcast for investors and analysts on Monday, December 18, 2023 at 8:30 am ET to discuss the latest seralutinib clinical data from the ongoing TORREY Phase 2 Open-Label Extension Study in PAH patients.
  • Seralutinib is a tyrosine kinase inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, specifically designed to be delivered via dry powder inhaler for the treatment of pulmonary hypertension.
  • The live audio webcast may be accessed through the “Events / Presentations” page in the “Investors” section of the Company's website at www.gossamerbio.com .
  • Alternatively, the conference call may be accessed through the following:
    A replay of the audio webcast will be available for 30 days on the “Investors” section of the Company's website, www.gossamerbio.com .